Sarcoidosis is a systemic inflammatory disease defined by the presence of aberrant granulomas affecting various organs. Due to its multisystem involvement, care of patients with established sarcoidosis becomes challenging, especially in the intensive care setting. While the lungs are typically involved, extrapulmonary manifestations also occur either concurrently or exclusively within a significant proportion of patients, complicating diagnostic and management decisions. The scope of this review is to focus on what considerations are necessary in the evaluation and management of patients with known sarcoidosis and their associated complications within a cardiopulmonary and critical care perspective.
HeijnenTWilmerABlockmansDHenckaertsL. Outcome of patients with systemic diseases admitted to the medical intensive care unit of a tertiary referral hospital: a single-centre retrospective study. Scand J Rheumatol. 2016;45(2):146–150.
3.
TukeyMHBermanJSBoggsDAWhiteLFRosenbergLCozierYC. Mortality among African American women with sarcoidosis: data from the Black Women’s Health Study. Sarcoidosis Vasc Diffuse Lung Dis. 2013;30(2):128–133.
4.
CoultasDBZumwaltREBlackWCSobonyaRE. The epidemiology of interstitial lung diseases. Am J Respir Crit Care Med. 1994;150(4):967–972.
BaydurA. Mechanical ventilation in interstitial lung disease: which patients are likely to benefit?Chest. 2008;133(5):1062–1063.
7.
Fernández-PérezERYilmazMJenadH, et al.Ventilator settings and outcome of respiratory failure in chronic interstitial lung disease. Chest. 2008;133(5):1113–1119.
8.
GannonWDLedererDJBiscottiM, et al.Outcomes and mortality prediction model of critically ill adults with acute respiratory failure and interstitial lung disease. Chest. 2018;153(6):1387–1395.
9.
GüngörGTatarDSaltürkC, et al.Why do patients with interstitial lung diseases fail in the ICU? A 2-center cohort study. Respir Care. 2013;58(3):525–531.
10.
HuapayaJAWilfongEMHardenCTBrowerRGDanoffSK. Risk factors for mortality and mortality rates in interstitial lung disease patients in the intensive care unit. Eur Respir Rev. 2018;27(150):180061.
11.
MallickS. Outcome of patients with idiopathic pulmonary fibrosis (IPF) ventilated in intensive care unit. Respir Med. 2008;102(10):1355–1359.
12.
TrudzinskiFCKaestnerFSchäfersHJ, et al.Outcome of patients with interstitial lung disease treated with extracorporeal membrane oxygenation for acute respiratory failure. Am J Respir Crit Care Med. 2016;193(5):527–533.
13.
Vial-DupuyASanchezODouvryB, et al.Outcome of patients with interstitial lung disease admitted to the intensive care unit. Sarcoidosis Vasc Diffuse Lung Dis. 2013;30(2):134–142.
14.
ZafraniLLemialeVLapidusN, et al.Acute respiratory failure in critically ill patients with interstitial lung disease. PLoS One. 2014;9(8):e104897.
15.
Cartin-CebaRKojicicMLiG, et al.Epidemiology of critical care syndromes, organ failures, and life-support interventions in a suburban US community. Chest. 2011;140(6):1447–1455.
16.
VincentJLSakrYRanieriVM. Epidemiology and outcome of acute respiratory failure in intensive care unit patients. Crit Care Med. 2003;31(4):S296–S299.
17.
FaverioPDe GiacomiFSardellaL, et al.Management of acute respiratory failure in interstitial lung diseases: overview and clinical insights. BMC Pulm Med. 2018;18(1):70.
18.
LeuschnerGBehrJ. Acute exacerbation in interstitial lung disease. Front Med (Lausanne). 2017;4:176.
19.
ArondiSValsecchiABorghesiAMontiS. Pulmonary sarcoidosis presenting with acute respiratory distress syndrome. Ann Thorac Med. 2016;11(1):79–81.
20.
LashariBHRazaAChanVWardW. Sarcoidosis presenting as acute respiratory distress syndrome. Case Rep Med. 2018;2018:6465180.
21.
SabbaghFGibbsCEfferenLS. Pulmonary sarcoidosis and the acute respiratory distress syndrome (ARDS). Thorax. 2002;57(7):655–656.
22.
FergusonNDFanECamporotaL, et al.The Berlin definition of ARDS: an expanded rationale, justification, and supplementary material. Intensive Care Med. 2012;38(10):1573–1582.
23.
PanselinasEJudsonMA. Acute pulmonary exacerbations of sarcoidosis. Chest. 2012;142(4):827–836.
24.
StarshinovaAAMalkovaAMBasantsovaNY, et al.Sarcoidosis as an autoimmune disease. Front Immunol. 2020;10:2933.
25.
ItoJNagataKMorimotoT, et al.Respiratory management of acute exacerbation of interstitial pneumonia using high-flow nasal cannula oxygen therapy: a single center cohort study. J Thorac Dis. 2019;11(1):103–112.
26.
KoyauchiTHasegawaHKanataK, et al.Efficacy and tolerability of high-flow nasal cannula oxygen therapy for hypoxemic respiratory failure in patients with interstitial lung disease with do-not-intubate orders: a retrospective single-center study. Respiration. 2018;96(4):323–329.
27.
MauriTTurriniCEroniaN, et al.Physiologic effects of high-flow nasal cannula in acute hypoxemic respiratory failure. Am J Respir Crit Care Med. 2017;195(9):1207–1215.
28.
FratJPThilleAWMercatA, et al.High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure. N Engl J Med. 2015;372(23):2185–2196.
29.
JohannsonKAPendharkarSRMathisonK, et al.Supplemental oxygen in interstitial lung disease: an art in need of science. Ann Am Thorac Soc. 2017;14(9):1373–1377.
30.
BesnierEHobeikaSNSeirS, et al.High-flow nasal cannula therapy: clinical practice in intensive care units. Ann Intensive Care. 2019;9(1):98.
31.
AlibertiSMessinesiGGamberiniS, et al.Non-invasive mechanical ventilation in patients with diffuse interstitial lung diseases. BMC Pulm Med. 2014;14:194.
32.
BatesJHDavisGSMajumdarAButnorKJSukiB. Linking parenchymal disease progression to changes in lung mechanical function by percolation. Am J Respir Crit Care Med. 2007;176(6):617–623.
33.
XuYSunQYuY, et al.Prone position ventilation support for acute exacerbation of interstitial lung disease?Clin Respir J. 2018;12(4):1372–1380.
34.
CokerRK. Guidelines for the use of corticosteroids in the treatment of pulmonary sarcoidosis. Drugs. 2007;67(8):1139–1147.
35.
HunninghakeGWCostabelUAndoM, et al.ATS/ERS/ WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and Other Granulomatous Disorders. Am J Respir Crit Care Med. 1999;160:736–755.
36.
JudsonMA. Corticosteroids in sarcoidosis. Rheum Dis Clin North Am. 2016;42(1):119–135, ix.
37.
BaughmanRPLowerEE. Treatment of sarcoidosis. Clin Rev Allergy Immunol. 2015;49(1):79–92.
38.
CulverDAJudsonMA. New advances in the management of pulmonary sarcoidosis. BMJ. 2019;367:l5553.
39.
UngprasertPRyuJHMattesonEL. Clinical manifestations, diagnosis, and treatment of sarcoidosis. Mayo Clin Proc Innov Qual Outcomes. 2019;3(3):358–375.
40.
ParamothayanSLassersonT. Treatments for pulmonary sarcoidosis. Respir Med. 2008;102(1):1–9.
41.
SchuttACBullingtonWMJudsonMA. Pharmacotherapy for pulmonary sarcoidosis: a Delphi consensus study. Respir Med. 2010;104(5):717–723.
42.
AdlerBLWangCJBuiTLSchilperoortHMArmstrongAW. Anti-tumor necrosis factor agents in sarcoidosis: a systematic review of efficacy and safety. Semin Arthritis Rheum. 2019;48(6):1093–1104.
43.
ParkMKFontanaJrBabaaliH, et al.Steroid-sparing effects of pentoxifylline in pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2009;26(2):121–131.
44.
TongZDaiHChenBAbdohZGuzmanJCostabelU. Inhibition of cytokine release from alveolar macrophages in pulmonary sarcoidosis by pentoxifylline: comparison with dexamethasone. Chest. 2003;124(4):1526–1532.
45.
BechtelJJStarrTIIIDantzkerDRBowerJS. Airway hyperreactivity in patients with sarcoidosis. Am Rev Respir Dis. 1981;124(6):759–761.
46.
MarciasSLeddaMAPerraRSeverinoCRosettiL. Aspecific bronchial hyperreactivity in pulmonary sarcoidosis. Sarcoidosis. 1994;11(2):118–122.
47.
OlafssonMSimonssonBGHanssonSB. Bronchial reactivity in patients with recent pulmonary sarcoidosis. Thorax. 1985;40(1):51–53.
48.
MorgenthauASTeirsteinAS. Sarcoidosis of the upper and lower airways. Expert Rev Respir Med. 2011;5(6):823–833.
49.
ChambellanATurbiePNunesHBraunerMBattestiJPValeyreD. Endoluminal stenosis of proximal bronchi in sarcoidosis: bronchoscopy, function, and evolution. Chest. 2005;127(2):472–481.
50.
PolychronopoulosVSPrakashUBS. Airway involvement in sarcoidosis. Chest. 2009;136(5):1371–1380.
51.
ShorrAFTorringtonKGHnatiukOW. Endobronchial involvement and airway hyperreactivity in patients with sarcoidosis. Chest. 2001;120(3):881–886.
52.
ViskumKVestboJ. Vital prognosis in intrathoracic sarcoidosis with special reference to pulmonary function and radiological stage. Eur Respir J. 1993;6(3):349–353.
53.
WestneyGEHabibSQuarshieA. Comorbid illnesses and chest radiographic severity in African-American sarcoidosis patients. Lung. 2007;185(3):131–137.
54.
WilsherMHopkinsRZengICornereMDouglasR. Prevalence of asthma and atopy in sarcoidosis. Respirology. 2012;17(2):285–290.
55.
CriadoESánchezMRamírezJ, et al.Pulmonary sarcoidosis: typical and atypical manifestations at high-resolution CT with pathologic correlation. Radiographics. 2010;30(6):1567–1586.
56.
DaviesCWTaskerADPadleySPDaviesRJGleesonFV. Air trapping in sarcoidosis on computed tomography: correlation with lung function. Clin Radiol. 2000;55(3):217–221.
57.
BaughmanRPLowerEE. Frequency of acute worsening events in fibrotic pulmonary sarcoidosis patients. Respir Med. 2013;107(12):2009–2013.
58.
JudsonMABaughmanRP. Worsening of pulmonary sarcoidosis. Curr Opin Pulm Med. 2014;20(5):508–516.
59.
DuréaultAChapelonCBiardL, et al.Severe infections in sarcoidosis: incidence, predictors and long-term outcome in a cohort of 585 patients. Medicine (Baltimore). 2017;96(49): e8846.
60.
UzunhanYNunesHJenyF, et al.Chronic pulmonary aspergillosis complicating sarcoidosis. Eur Respir J. 2017;49(6):1602396.
RochwergBAgarwalAZengL, et al.Remdesivir for severe Covid-19: a clinical practice guideline. BMJ. 2020;370:m2924.
67.
SiemieniukRABartoszkoJJGeL, et al.Drug treatments for Covid-19: living systematic review and network meta-analysis. BMJ. 2020;370: m2980.
68.
WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, SterneJACMurthyS, et al.Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA. 2020;324(13):1330.
69.
GyörfiAHKoppMMayM, et al.Glucocorticoid-induced relapse of COVID-19 in a patient with sarcoidosis. Ann Rheum Dis. 2020. doi:10.1136/annrheumdis-2020-218258
70.
ManansalaMAscoliCAlburquerqueAG, et al.Case series: COVID-19 in African American patients with sarcoidosis. Front Med (Lausanne). 2020;7:588527.
71.
SweissNJKorstenPSyedHJ, et al.When the game changes: guidance to adjust sarcoidosis management during the coronavirus disease 2019 pandemic. Chest. 2020;158(3):892–895.
72.
NahidPDormanSEAlipanahN, et al.Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: treatment of drug-susceptible tuberculosis. Clin Infect Dis. 2016;63(7):e147.
73.
LimperAHKnoxKSSarosiGA, et al.An official American Thoracic Society statement: treatment of fungal infections in adult pulmonary and critical care patients. Am J Respir Crit Care Med. 2011;183(1):96.
74.
SternAGreenHPaulMVidalLLeiboviciL. Prophylaxis for pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database Syst Rev. 2014;2014(10):CD005590.
75.
KrebsSGibbonsRB. Low-dose methotrexate as a risk factor for Pneumocystis carinii pneumonia. Mil Med. 1996;161(1):58–60.
76.
KaurNMahlTC. Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy: a review of 84 cases. Dig Dis Sci. 2007;52(6):1481–1484.
77.
ParejaJGGarlandRKozielH. Use of adjunctive corticosteroids in severe adult non-HIV Pneumocystis carinii pneumonia. Chest. 1998;113(5):1215.
78.
SepkowitzKA. Pneumocystis carinii pneumonia in patients without AIDS. Clin Infect Dis. 1993;17(2):S416–422.
79.
KosmidisCDenningDW. The clinical spectrum of pulmonary aspergillosis. Thorax. 2015;70(3):270–277.
80.
PenaTASoubaniAOSamavatiL. Aspergillus lung disease in patients with sarcoidosis: a case series and review of the literature. Lung. 2011;189(2):167–172.
81.
Alastruey-IzquierdoACadranelJFlickH, et al.Treatment of chronic pulmonary aspergillosis: current standards and future perspectives. Respiration. 2018;96(2):159–170.
82.
DubreySWSharmaRUnderwoodRMittalT. Cardiac sarcoidosis: diagnosis and management. Postgrad Med J. 2015;91(1077):384–394.
83.
TanJLFongHKBiratiEYHanY. Cardiac sarcoidosis. Am J Cardiol. 2019;123(3):513–522.
84.
NunesHFreynetONaggaraN, et al.Cardiac sarcoidosis. Semin Respir Crit Care Med. 2010;31(4):428–441.
TerasakiFAzumaAAnzaiT, et al.JCS 2016 guideline on diagnosis and treatment of cardiac sarcoidosis—digest version. Circ J. 2019;83(11):2329–2388.
87.
DubreySWFalkRH. Diagnosis and management of cardiac sarcoidosis. Prog Cardiovasc Dis. 2010;52(4):336–346.
88.
YazakiYIsobeMHiroeM, et al.Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone. Am J Cardiol. 2001;88(9):1006–1010.
89.
AyyalaUSNairAPPadillaML. Cardiac sarcoidosis. Clin Chest Med. 2008;29(3):493–508, ix.
90.
HugginsJTDoelkenPSahnSAKingLJudsonMA. Pleural effusions in a series of 181 outpatients with sarcoidosis. Chest. 2006;129(6):1599–1604.
91.
ChusidELSiltzbachLE. Sarcoidosis of the pleura. Ann Intern Med. 1974;81(2):190–194.
92.
NichollsAJFriendJALeggeJS. Sarcoid pleural effusion: three cases and review of the literature. Thorax. 1980;35(4):277–281.
93.
MayoPHGoltzHRTafreshiMDoelkenP. Safety of ultrasound-guided thoracentesis in patients receiving mechanical ventilation. Chest. 2004;125(3):1059–1062.
94.
TalmorMHydoLGershenwaldJGBariePS. Beneficial effects of chest tube drainage of pleural effusion in acute respiratory failure refractory to positive end-expiratory pressure ventilation. Surgery. 1998;123(2):137–143.
95.
KobakS. Sarcoidosis: a rheumatologist’s perspective. Ther Adv Musculoskelet Dis. 2015;7(5):196–205.
96.
TeirsteinA. Neuromuscular sarcoidosis. Semin Respir Crit Care Med. 2002;23(6):505–512.
97.
BaydurAPandyaKSharmaOPKanelGCCarlsonM. Control of ventilation, respiratory muscle strength, and granulomatous involvement of skeletal muscle in patients with sarcoidosis. Chest. 1993;103(2):396–402.
98.
BaydurAAlsalekMLouieSGSharmaOP. Respiratory muscle strength, lung function, and dyspnea in patients with sarcoidosis. Chest. 2001;120(1):102–108.
99.
DewberryRGSchneiderBFCaleWFPhillipsLHII. Sarcoid myopathy presenting with diaphragm weakness. Muscle Nerve. 1993;16(8):832–835.
100.
OstDYeldandiACugellD.Acute sarcoid myositis with respiratory muscle involvement. Case report and review of the literature. Chest. 1995;107(3):879–882.
101.
ChangJCDriverAGTownsendCAKatariaYP. Hemoptysis in sarcoidosis. Sarcoidosis. 1987;4(1):49–54.
102.
JudsonMA.The clinical features of sarcoidosis: a comprehensive review. Clin Rev Allergy Immunol. 2015;49(1):63–78.
103.
MorrisseyBMEvansSJ. Severe bronchiectasis. Clin Rev Allergy Immunol. 2003;25(3):233–247.
104.
RadchenkoCAlraiyesAHShojaeS. A systematic approach to the management of massive hemoptysis. J Thorac Dis. 2017;9(10):S1069–S1086.
ConlanAAHurwitzSS. Management of massive haemoptysis with the rigid bronchoscope and cold saline lavage. Thorax. 1980;35(12):901–904.
107.
KhooKLLeePMehtaAC. Endobronchial epinephrine: confusion is in the air. Am J Respir Crit Care Med. 2013;187(10):1137–1138.
108.
CrawshawAPWottonCJYeatesDGRGoldacreMJHoL-P. Evidence for association between sarcoidosis and pulmonary embolism from 35-year record linkage study. Thorax. 2011;66(5):447–448.
109.
SwigrisJJOlsonALHuieTJ, et al.Increased risk of pulmonary embolism among US decedents with sarcoidosis from 1988 to 2007. Chest. 2011;140(5):1261–1266.
110.
PerezRLDuncanAHunterRLStatonGWJr. Elevated D dimer in the lungs and blood of patients with sarcoidosis. Chest. 1993;103(4):1100–1106.
111.
ShorrAFHnatiukOW. Circulating D dimer in patients with sarcoidosis. Chest. 2000;117(4):1012–1016.
112.
VorselaarsADMSnijderRJGruttersJC. Increased number of pulmonary embolisms in sarcoidosis patients. Chest. 2012;141(3):826–827.
ShlobinOABaughmanRP. Sarcoidosis-associated pulmonary hypertension. Semin Respir Crit Care Med. 2017;38(4):450–462.
115.
HandaTNagaiSMikiS, et al.Incidence of pulmonary hypertension and its clinical relevance in patients with sarcoidosis. Chest. 2006;129(5):1246–1252.
116.
MaimonNSalzLShershevskyYMatveychukAGuberAShitritD. Sarcoidosis-associated pulmonary hypertension in patients with near-normal lung function. Int J Tuberc Lung Dis. 2013;17(3):406–411.
117.
ShorrAFHelmanDLDaviesDBNathanSD. Pulmonary hypertension in advanced sarcoidosis: epidemiology and clinical characteristics. Eur Respir J. 2005;25(5):783–788.
118.
SavaleLWeatheraldJJaïsX, et al.Acute decompensated pulmonary hypertension. Eur Respir Rev. 2017;26(146):170092.
119.
LiuHLChenXYLiJR, et al.Efficacy and safety of pulmonary arterial hypertension-specific therapy in pulmonary arterial hypertension: a meta-analysis of randomized controlled trials. Chest. 2016;150(2):353–366.
BaughmanRPCulverDACordovaFC, et al.Bosentan for sarcoidosis-associated pulmonary hypertension: a double-blind placebo controlled randomized trial. Chest. 2014;145(4):810–817.
122.
CondliffeRElliotCAHurdmanJ, et al.Ambrisentan therapy in pulmonary hypertension: clinical use and tolerability in a referral centre. Ther Adv Respir Dis. 2014;8(3):71–77.
123.
JudsonMAHighlandKBKwonS, et al.Ambrisentan for sarcoidosis associated pulmonary hypertension. Sarcoidosis Vasc Diffuse Lung Dis. 2011;28(2):139–145.
124.
FordHJBaughmanRPArisREngelPDonohueJF. Tadalafil therapy for sarcoidosis-associated pulmonary hypertension. Pulm Circ. 2016;6(4):557–562.
125.
MilmanNBurtonCMIversenMVidebaekRJensenCVCarlsenJ. Pulmonary hypertension in end-stage pulmonary sarcoidosis: therapeutic effect of sildenafil?J Heart Lung Transplant. 2008;27(3):329–334.
126.
MilmanNSvendsenCBIversenMVidebaekRCarlsenJ. Sarcoidosis-associated pulmonary hypertension: acute vasoresponsiveness to inhaled nitric oxide and the relation to long-term effect of sildenafil. Clin Respir J. 2009;3(4):207–213.
127.
GhofraniHAGalièNGrimmingerF, et al.Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med. 2013; 369(4):330–340.
128.
AbstonEMollMHonSGovenderPBermanJFarberH. Long-term outcomes of epoprostenol therapy in sarcoid associated pulmonary hypertension. Sarcoidosis VDLD [Internet]. 2020;37(2):184–191.
129.
BaughmanRPJudsonMALowerEE, et al.Inhaled iloprost for sarcoidosis associated pulmonary hypertension. Sarcoidosis Vasc Diffuse Lung Dis. 2009;26(2):110–120.
130.
BonhamCAOldhamJMGomberg-MaitlandMVijR. Prostacyclin and oral vasodilator therapy in sarcoidosis-associated pulmonary hypertension: a retrospective case series. Chest. 2015;148(4):1055–1062.
PrestonIRKlingerJRLandzbergMJHoutchensJNelsonDHillNS. Vasoresponsiveness of sarcoidosis-associated pulmonary hypertension. Chest. 2001;120(3):866–872.
133.
SimonneauGTorbickiAHoeperMM, et al.Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. Eur Respir J. 2012;40(4):874–880.
134.
MuzevichKMChohanHGrinnanDC. Management of pulmonary vasodilator therapy in patients with pulmonary arterial hypertension during critical illness. Crit Care. 2014;18(5):523.
135.
PrestonIRSaglianiKDRobertsKE, et al.Comparison of acute hemodynamic effects of inhaled nitric oxide and inhaled epoprostenol in patients with pulmonary hypertension. Pulm Circ. 2013;3(1):68–73.
136.
WaxmanABMcElderryHTGomberg-MaitlandM, et al.Totally implantable IV treprostinil therapy in pulmonary hypertension assessment of the implantation procedure. Chest. 2017;152(6):1128–1134.
137.
MermelLAAllonMBouzaE, et al.Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;49(1):1–45.
138.
Coz YatacoAAguinaga MezaMBuchKPDisselkampMA. Hospital and intensive care unit management of decompensated pulmonary hypertension and right ventricular failure. Heart Fail Rev. 2016;21(3):323–346.
139.
JentzerJCMathierMA. Pulmonary hypertension in the intensive care unit. J Intensive Care Med. 2016;31(6):369–385.
140.
GrinsteinJGomberg-MaitlandM. Management of pulmonary hypertension and right heart failure in the intensive care unit. Curr Hypertens Rep. 2015;17(5):32.
141.
SztrymfBSouzaRBertolettiL, et al.Prognostic factors of acute heart failure in patients with pulmonary arterial hypertension. Eur Respir J. 2010;35(6):1286–1293.
142.
KurzynaMZyłkowskaJFijałkowskaA, et al.Characteristics and prognosis of patients with decompensated right ventricular failure during the course of pulmonary hypertension. Kardiol Pol. 2008;66(10):1033–1039; discussion 1040-1.
143.
HoeperMMGrantonJ. Intensive care unit management of patients with severe pulmonary hypertension and right heart failure. Am J Respir Crit Care Med. 2011;184(10):1114–1124.
144.
OlssonKMHalankMEgenlaufB, et al.Decompensated right heart failure, intensive care and perioperative management in patients with pulmonary hypertension: updated recommendations from the Cologne Consensus Conference 2018. Int J Cardiol. 2018;272S:46–52.
145.
PriceLCWortSJFinneySJMarinoPSBrettSJ. Pulmonary vascular and right ventricular dysfunction in adult critical care: current and emerging options for management: a systematic literature review. Crit Care. 2010;14(5):R169.
146.
ZamanianRTHaddadFDoyleRLWeinackerAB. Management strategies for patients with pulmonary hypertension in the intensive care unit. Crit Care Med. 2007;35(9):2037–2050.
147.
BartolomeSDTorresF. Severe pulmonary arterial hypertension: stratification of medical therapies, mechanical support, and lung transplantation. Heart Fail Rev. 2016;21(3):347–356.
148.
RosenthalDGBravoPEPattonKKGoldbergerZD. Management of arrhythmias in cardiac sarcoidosis. Clin Cardiol. 2015;38(10):635–640.
149.
SelanJCMichaelsonMFanburgBLEstesNA. Evaluation and management of heart rhythm disturbances due to cardiac sarcoidosis. Heart Lung Circ. 2014;23(12):1100–1109.
150.
BirnieDHNeryPBHaACBeanlandsRS. Cardiac sarcoidosis. J Am Coll Cardiol. 2016;68(4):411–421.
151.
KusanoKFSatomiK. Diagnosis and treatment of cardiac sarcoidosis. Heart. 2016;102(3):184–190.
152.
YadaHSoejimaK. Management of arrhythmias associated with cardiac sarcoidosis. Korean Circ J. 2019;49(2):119–133.
153.
BirnieDHSauerWHBogunF, et al.HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm. 2014;11(7):1305–1323.
154.
KumarSBarbhaiyaCNagashimaK, et al.Ventricular tachycardia in cardiac sarcoidosis: characterization of ventricular substrate and outcomes of catheter ablation. Circ Arrhythm Electrophysiol. 2015;8(1):87–93.
155.
OkadaDRSmithJDerakhshanA, et al.Ventricular arrhythmias in cardiac sarcoidosis. Circulation. 2018;138(12):1253–1264.
156.
BargoutRKellyRF. Sarcoid heart disease: clinical course and treatment. Int J Cardiol. 2004;97(2):173–182.
157.
JeficDJoelBGoodE, et al.Role of radiofrequency catheter ablation of ventricular tachycardia in cardiac sarcoidosis: report from a multicenter registry. Heart Rhythm. 2009;6(2):189–195.
158.
WintersSLCohenMGreenbergS, et al.Sustained ventricular tachycardia associated with sarcoidosis: assessment of the underlying cardiac anatomy and the prospective utility of programmed ventricular stimulation, drug therapy and an implantable antitachycardia device. J Am Coll Cardiol. 1991;18(4):937–943.
159.
NaruseYSekiguchiYNogamiA, et al.Systematic treatment approach to ventricular tachycardia in cardiac sarcoidosis. Circ Arrhythm Electrophysiol. 2014;7(3):407–413.
160.
SlivnickJABetzJKalbfleischSCrouserEDKahwashR.High-dose intravenous glucocorticoids are effective in the acute management of ventricular arrhythmias in cardiac sarcoidosis: a case series. HeartRhythm Case Rep. 2020;6(10):706–710.
161.
IannuzziMCRybickiBATeirsteinAS. Sarcoidosis. N Engl J Med. 2007;357(21):2153–2165.
162.
PapageorgiouNProvidênciaRBronisK, et al.Catheter ablation for ventricular tachycardia in patients with cardiac sarcoidosis: a systematic review. Europace. 2018;20(4):682–691.
163.
Viles-GonzalezJFPastoriLFischerAWisniveskyJPGoldmanMGMehtaD. Supraventricular arrhythmias in patients with cardiac sarcoidosis prevalence, predictors, and clinical implications. Chest. 2013;143(4):1085–1090.
164.
MehtaDWillnerJMAkhrassPR. Atrial fibrillation in cardiac sarcoidosis. J Atr Fibrillation. 2015;8(4):1288.
165.
WillnerJMViles-GonzalezJFCoffeyJOMorgenthauASMehtaD. Catheter ablation of atrial arrhythmias in cardiac sarcoidosis. J Cardiovasc Electrophysiol. 2014;25(9):958–963.
166.
WannLSCurtisABJanuaryCT, et al.2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (Updating the 2006 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2011;57(2):223–242.
167.
Gea-BanaclocheJCOpalSMJorgensenJCarcilloJASepkowitzKACordonnierC. Sepsis associated with immunosuppressive medications: an evidence-based review. Crit Care Med. 2004;32(11):S578–590.
168.
JosephRMHunterALRayDWDixonWG. Systemic glucocorticoid therapy and adrenal insufficiency in adults: a systematic review. Semin Arthritis Rheum. 2016;46(1):133–141.
169.
RichterBNeisesGClarC.Glucocorticoid withdrawal schemes in chronic medical disorders. A systematic review. Endocrinol Metab Clin North Am. 2002;31(3):751.
170.
DorinRIQuallsCRCrapoLM. Diagnosis of adrenal insufficiency. Ann Intern Med. 2003;139(3):194.
